Sangamo Therapeutics Files 8-K
Ticker: SGMO · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting
Related Tickers: SGMO
TL;DR
SANGAMO THERAPEUTICS FILED AN 8-K ON AUG 6 - FINANCIALS AND OPERATIONS UPDATE.
AI Summary
Sangamo Therapeutics, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signals a formal update from Sangamo Therapeutics regarding its financial status and operational results, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not inherently contain new negative information, but rather a procedural update.
Key Players & Entities
- SANGAMO THERAPEUTICS, INC. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- 501 Canal Blvd. (address) — Principal executive offices
- Richmond, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing by Sangamo Therapeutics?
The primary purpose of this 8-K filing is to report on Sangamo Therapeutics, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
On what date was this 8-K filing reported?
The 8-K filing was reported on August 6, 2024.
What is Sangamo Therapeutics, Inc.'s principal executive office address?
Sangamo Therapeutics, Inc.'s principal executive office is located at 501 Canal Blvd., Richmond, California 94804.
What is the IRS Employer ID Number for Sangamo Therapeutics, Inc.?
The IRS Employer ID Number for Sangamo Therapeutics, Inc. is 68-0359556.
What is the SIC code for Sangamo Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Sangamo Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-06 16:01:30
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Global
Filing Documents
- sgmo-20240806.htm (8-K) — 33KB
- exhibit-991080624.htm (EX-99.1) — 116KB
- logo.gif (GRAPHIC) — 43KB
- 0001628280-24-035160.txt ( ) — 345KB
- sgmo-20240806.xsd (EX-101.SCH) — 2KB
- sgmo-20240806_lab.xml (EX-101.LAB) — 21KB
- sgmo-20240806_pre.xml (EX-101.PRE) — 12KB
- sgmo-20240806_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2024, Sangamo Therapeutics, Inc. ("Sangamo") issued a press release announcing its financial results for the quarter ended June 30, 2024 (the "Press Release"). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release regarding financial results dated August 6 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: August 6, 2024 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Senior Vice President, General Counsel and Corporate Secretary